Lung cancer trials in Belgium

In Belgium 127 Also abroad 2747

127 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Gent, Leuven, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 1Taking people
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Where
Edegem, Hasselt, Leuven
Age
18 years and over
People
93 worldwide
Run by
Gilead Sciences Inc.
See details and how to joinNCT05007782 · EU 2022-501684-40-00
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Charleroi, Gent, Mons
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 1/2Taking people
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Where
Edegem, Namur
Age
18 years and over
People
118 worldwide
Run by
MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07407933
No phaseTaking people
Identification of Changes in Cancer-related Fatigue and Physical Activity and Their Association in Patients With Inoperable Lung Cancer: a Longitudinal Observational Study
Where
Ghent
Age
18 years and over
People
50
Run by
University Hospital, Ghent
See details and how to joinNCT07799974
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Brugge, Hasselt, Kortrijk, Leuven, Mechelen, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Charleroi
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Charleroi, Hasselt, Liège, Roeselare, Sint-Niklaas
Age
18 years and over
People
355 worldwide
Run by
Gilead Sciences Inc.
See details and how to join2024-515884-69-00
Phase 2Taking people
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
Where
Anderlecht, Edegem, Leuven, Liège
Age
18 years and over
People
36 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01
Phase 1Taking people
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Where
Anderlecht, Antwerp, Gent
Age
18 years to 99 years
People
160 worldwide
Run by
Amgen
See details and how to joinNCT07531095 · EU 2025-522888-15-00
Phase 1/2Taking people
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Where
Antwerp, Brussels, Liège
Age
18 years and over
People
230 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT05985655
Phase 1Taking people
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Where
Edegem, Gent, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
138 worldwide
Run by
Deuteroncology
See details and how to join2023-504897-39-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Hasselt, Leuven, Liège, Roeselare, Yvoir
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Anderlecht, Leuven
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Edegem, Hasselt, Liège, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 1Taking people
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Where
Leuven
Age
18 years and over
People
307 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT05433142 · EU 2024-513619-28-00
Phase 1Taking people
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Where
Edegem, Ghent
Age
18 years and over
People
434 worldwide
Run by
Amgen
See details and how to joinNCT07094113
Phase 2Taking people
A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)
Where
Jette
Age
18 years and over
People
20
Run by
UZ Brussel
See details and how to join2024-514138-19-00
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Brussels
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Gent, Leuven
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Anderlecht
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Taking people
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Where
Brussels, Edegem, Leuven
Age
18 years and over
People
710 worldwide
Run by
Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00
Phase 3Taking people
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
Where
Brasschaat, Charleroi, Hasselt, Kortrijk, Namur
Age
18 years and over
People
147 worldwide
Run by
Shanghai Junshi Biosciences Co. Ltd.
See details and how to join2023-507097-41-01
Phase 2Taking people
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Where
Edegem, Jette, Liège
Age
18 years to 70 years
People
170 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00
Phase 1Taking people
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Where
Gent, Leuven, Liège
Age
18 years and over
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00